BioLife Solutions (BLFS) awards 8,170 restricted shares to director

Rhea-AI Filing Summary

GOSWAMI JOYDEEP reported acquisition or exercise transactions in this Form 4 filing.

BioLife Solutions Inc. director Joydeep Goswami received a grant of 8,170 shares of restricted common stock, recorded at a price of $0 per share as a stock award rather than a market purchase. Following this grant, his directly held common stock increased to 53,156 shares.

The restricted stock was granted under the BioLife Solutions 2023 Performance Incentive Plan and, according to the disclosure, will fully vest on the first anniversary of the vesting date of January 2, 2026.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider GOSWAMI JOYDEEP

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	8,170	$0.00	--

Holdings After Transaction: Common Stock — 53,156 shares (Direct)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

GOSWAMI JOYDEEP

(Last) (First) (Middle)

3303 MONTE VILLA PARKWAY

SUITE 310

(Street)

BOTHELL WA 98021

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
BIOLIFE SOLUTIONS INC [ BLFS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
02/24/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/24/2026		A		8,170	A	(1)	53,156	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The restricted stock was granted pursuant to the BioLife Solutions 2023 Performance Incentive Plan and fully vests on the first anniversary of the vesting date of January 2, 2026

Remarks:

	/s/ Joydeep Goswami	02/26/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did BioLife Solutions (BLFS) report for Joydeep Goswami?

BioLife Solutions reported that director Joydeep Goswami received a grant of 8,170 shares of restricted common stock. The award was issued at a stated price of $0 per share as compensation, increasing his directly held common stock position to 53,156 shares after the transaction.

How many BioLife Solutions (BLFS) shares does Joydeep Goswami own after this Form 4?

After the reported grant, Joydeep Goswami directly holds 53,156 shares of BioLife Solutions common stock. This total reflects the addition of 8,170 restricted shares awarded to him, as disclosed in the Form 4 insider trading report filed for the relevant transaction date.

Was the BioLife Solutions (BLFS) Form 4 transaction a market purchase or a stock award?

The BioLife Solutions Form 4 shows a stock award, not a market purchase. Transaction code A and a reported price of $0 per share indicate a grant or other acquisition of restricted stock as compensation, rather than an open-market buy by the director.

What plan governed the restricted stock grant to the BioLife Solutions (BLFS) director?

The restricted stock granted to director Joydeep Goswami was issued under the BioLife Solutions 2023 Performance Incentive Plan. The filing specifies this plan as the source of the award, confirming it as part of the company’s established equity-based compensation framework for eligible participants.

When do the restricted BioLife Solutions (BLFS) shares granted to Joydeep Goswami fully vest?

The restricted shares granted to Joydeep Goswami fully vest on the first anniversary of the vesting date of January 2, 2026. This vesting schedule is described in the footnote to the Form 4, outlining when the awarded restricted stock will become fully vested for the director.